A detailed history of Price T Rowe Associates Inc transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 54,714 shares of BLUE stock, worth $24,074. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,714
Previous 54,714 -0.0%
Holding current value
$24,074
Previous $71,000 23.94%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.91 - $1.75 $26,492 - $50,947
29,113 Added 113.72%
54,714 $71,000
Q4 2023

Feb 14, 2024

BUY
$1.32 - $4.83 $3,175 - $11,620
2,406 Added 10.37%
25,601 $36,000
Q3 2023

Nov 14, 2023

SELL
$3.02 - $4.05 $60,756 - $81,477
-20,118 Reduced 46.45%
23,195 $71,000
Q2 2023

Aug 14, 2023

BUY
$2.79 - $5.03 $25,734 - $46,396
9,224 Added 27.06%
43,313 $143,000
Q1 2023

May 15, 2023

BUY
$3.14 - $8.22 $15,511 - $40,606
4,940 Added 16.95%
34,089 $109,000
Q4 2022

Feb 14, 2023

BUY
$5.77 - $8.49 $5,366 - $7,895
930 Added 3.3%
29,149 $202,000
Q3 2022

Nov 14, 2022

BUY
$3.75 - $7.39 $26,355 - $51,936
7,028 Added 33.17%
28,219 $179,000
Q2 2022

Aug 15, 2022

BUY
$2.94 - $5.23 $1,490 - $2,651
507 Added 2.45%
21,191 $88,000
Q1 2022

May 16, 2022

BUY
$4.07 - $10.6 $6,121 - $15,942
1,504 Added 7.84%
20,684 $100,000
Q4 2021

Feb 14, 2022

SELL
$8.96 - $16.31 $81,303 - $147,996
-9,074 Reduced 32.12%
19,180 $192,000
Q3 2021

Nov 15, 2021

BUY
$11.24 - $21.0 $663 - $1,239
59 Added 0.21%
28,254 $540,000
Q2 2021

Aug 16, 2021

SELL
$18.04 - $22.09 $16.7 Million - $20.4 Million
-923,645 Reduced 97.04%
28,195 $902,000
Q1 2021

May 17, 2021

SELL
$16.59 - $33.89 $1.36 Million - $2.78 Million
-81,980 Reduced 7.93%
951,840 $28.7 Million
Q4 2020

Feb 16, 2021

BUY
$27.5 - $37.92 $28.4 Million - $39.2 Million
1,033,820 New
1,033,820 $44.7 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $33.9M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.